Collaborative Arrangement, Contingent Consideration, Range Of Outcomes, Maximum, Amount

No definition available.

Name:	supn_CollaborativeArrangementContingentConsiderationRangeOfOutcomesMaximumAmount
Namespace Prefix:	supn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Number Of Studies

+ References

No definition available.

+ Details

Name:	supn_CollaborativeArrangementNumberOfStudies
Namespace Prefix:	supn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Payment For One Time Fee

+ References

No definition available.

+ Details

Name:	supn_CollaborativeArrangementPaymentForOneTimeFee
Namespace Prefix:	supn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Threshold For Development Costs Payments

+ References

No definition available.

+ Details

Name:	supn_CollaborativeArrangementThresholdForDevelopmentCostsPayments
Namespace Prefix:	supn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Purchase Commitment, Annual Minimum Amount Committed

+ References

No definition available.

+ Details

Name:	supn_PurchaseCommitmentAnnualMinimumAmountCommitted
Namespace Prefix:	supn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:	us-gaap_EquitySecuritiesFvNiCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermPurchaseCommitmentLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of defendants named in a legal action.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

+ Details

Name:	us-gaap_LossContingencyNumberOfDefendants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Subparagraph (ee)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-17

+ Details

Name:	us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 5A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A

+ Details

Name:	us-gaap_VariableInterestEntityOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_LitigationCaseAxis=supn_MergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=supn_DerivativeLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=supn_MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=supn_NavitorPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) $ in Thousands, € in Millions				1 Months Ended		6 Months Ended
	May 22, 2025 defendant	May 13, 2025 defendant	Mar. 26, 2025 defendant	Jun. 30, 2026 USD ($)	Apr. 30, 2020 USD ($)	Jun. 30, 2026 USD ($) plaintiff	Jun. 30, 2025 USD ($)	Jun. 30, 2026 EUR (€)	Apr. 01, 2026 USD ($) study
Long-term Purchase Commitment [Line Items]
Payment of contingent consideration				$ 10,000		$ 22,208	$ 4,900
Merger Agreement \| Sage Litigation
Long-term Purchase Commitment [Line Items]
Number of plaintiff \| plaintiff						2
Derivative Litigation \| Sage Litigation
Long-term Purchase Commitment [Line Items]
Number of defendants \| defendant	16	16	16
USWM Acquisition
Long-term Purchase Commitment [Line Items]
Annual minimum purchase quantity requirement amount \| €								€ 3.0
Navitor Pharmaceuticals, Inc.
Long-term Purchase Commitment [Line Items]
Threshold for development costs payments					$ 50,000
Collaborative arrangement, payment for one time fee					10,000
Collaborative arrangement, number of studies \| study									1
Collaborative arrangement, contingent consideration, maximum									$ 350,000
Navitor Pharmaceuticals, Inc. \| Variable Interest Entity, Not Primary Beneficiary
Long-term Purchase Commitment [Line Items]
Investments					$ 15,000
VIE, qualitative or quantitative information, ownership percentage					13.00%